BAT FY2026 growth seen at lower end of range; shares fall

British American Tobacco shares fell 1.02% after management said FY2026 revenue and adjusted profit-from-operations growth should land at the lower ends of its 3-5% and 4-6% constant-currency guidance ranges, respectively. Adjusted diluted EPS growth is still expected around the midpoint of the 5-8% range, though spot FX implies a 2-2.5% translation headwind. BAT reiterated Horizon 2030 plans for mid-teens New Category revenue growth and a contribution margin of at least 30%, while targeting 2.0-2.5x leverage by year-end and continuing shareholder cash returns.

Analysis

The important read-through is not the modest guidance reset but the earnings-quality gap: BTI is asking investors to underwrite a 2030 margin outcome while near-term reported EPS remains exposed to translation effects and a still-material financing burden. That combination limits the likelihood of a durable multiple re-rating over the next 1-3 months, even if the dividend remains a valuation support. The key operating proof point is whether reduced-risk products can demonstrate incremental category profit rather than merely shifting combustible consumers into lower-margin formats.

Competitive risk is asymmetric versus Philip Morris (PM), whose smoke-free platform has more established scale and has historically warranted a higher-quality growth multiple. Altria (MO) is the cleaner domestic-income alternative for investors seeking tobacco yield without GBP translation risk, although its U.S. nicotine-pouch execution remains the critical variable. A stronger dollar would amplify the ADR's reported-earnings pressure; conversely, GBP weakness or evidence of faster new-category mix gains could rapidly reverse relative underperformance.

Consensus may overvalue the stated long-dated margin target because achieving it likely requires sustained premiumization, marketing investment, and favorable regulation simultaneously. Over 6-18 months, leverage reduction can free capital-return capacity, but only if underlying cash conversion holds after investment in reduced-risk products. Watch next results for constant-currency new-category revenue growth, category contribution margin, net-debt/EBITDA trajectory, and any reduction in cash-return commitments; a miss on any two would turn the story from income-supported to a potential value trap.

Key Decisions for Investors

• Maintain an underweight in BTI for the next 1-3 months; do not add solely on the initial price weakness. Reassess after the next earnings release if new-category growth and contribution margin accelerate while net leverage declines toward the target range.
• For tobacco exposure, consider a 3-6 month relative-value pair: long PM / short BTI, sized beta-neutral. PM offers better exposure to proven smoke-free monetization, while BTI carries greater execution and FX sensitivity; exit if BTI's new-category margin inflects materially faster than PM's smoke-free profitability.
• Income-focused portfolios should compare BTI against MO rather than treat BTI's yield as a standalone signal. Favor MO only if its nicotine-pouch retail momentum remains intact; the trade is invalidated by material U.S. share losses or adverse FDA action affecting oral nicotine.
• Set a catalyst alert around GBP/USD and BTI's reported-EPS bridge: sustained GBP strength against the dollar or a larger-than-expected translation drag argues for further downside to estimates; GBP weakness plus confirmation of stable cash conversion is the principal near-term cover signal for any BTI short.